A detailed history of Satovsky Asset Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Satovsky Asset Management LLC holds 5,315 shares of BMY stock, worth $309,492. This represents 0.06% of its overall portfolio holdings.

Number of Shares
5,315
Previous 5,249 1.26%
Holding current value
$309,492
Previous $217,000 26.73%
% of portfolio
0.06%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$39.66 - $51.75 $2,617 - $3,415
66 Added 1.26%
5,315 $275,000
Q2 2024

Aug 02, 2024

BUY
$40.25 - $52.99 $2,777 - $3,656
69 Added 1.33%
5,249 $217,000
Q1 2024

Apr 23, 2024

SELL
$47.98 - $54.4 $45,005 - $51,027
-938 Reduced 15.33%
5,180 $280,000
Q4 2023

Jan 23, 2024

BUY
$48.48 - $57.85 $2,763 - $3,297
57 Added 0.94%
6,118 $313,000
Q3 2023

Oct 23, 2023

BUY
$57.89 - $64.73 $2,720 - $3,042
47 Added 0.78%
6,061 $351,000
Q2 2023

Jul 28, 2023

BUY
$63.71 - $70.74 $8,983 - $9,974
141 Added 2.4%
6,014 $384,000
Q1 2023

Apr 26, 2023

BUY
$65.71 - $74.53 $68,206 - $77,362
1,038 Added 21.47%
5,873 $407,000
Q4 2022

Jan 24, 2023

BUY
$68.48 - $81.09 $2,328 - $2,757
34 Added 0.71%
4,835 $0
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $4 - $2,689
35 Added 0.73%
4,801 $341,000
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $2,396 - $2,639
33 Added 0.7%
4,766 $367,000
Q1 2022

May 03, 2022

BUY
$61.48 - $73.72 $2,397 - $2,875
39 Added 0.83%
4,733 $346,000
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $2,145 - $2,500
40 Added 0.86%
4,694 $293,000
Q3 2021

Nov 08, 2021

BUY
$59.17 - $69.31 $1,952 - $2,287
33 Added 0.71%
4,654 $275,000
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $286,086 - $311,547
4,621 New
4,621 $309,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Satovsky Asset Management LLC Portfolio

Follow Satovsky Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Satovsky Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Satovsky Asset Management LLC with notifications on news.